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In a multisubtype approach to HIV-1 vaccination, mice were immunized with HIV-1 envelope gp160 genes from subtypes
A, B, and C. Subsequently the mice were challenged with syngeneic primary splenocytes infected with a HIV-1/MuLV
pseudovirus carrying a subtype B genome. HIV-specific immune responses and protection were strongest in the group of
animals immunized with a combination of subtype A, B, and C specific gp160 genes as compared to subtype B only.
Immunization with the combination of the cross-reactive subtypes A and C envelope genes induced HIV-specific immune
responses but did not result in significant protection to challenge with subtype B infected cells. From this we conclude that
immunization with the envelope genes from several HIV-1 subtypes may indeed enhance immune responses. This study
shows that by using a mix of subtype envelope genes, an enhanced protective immunity can be obtained experimentally,
potentially also in humans. © 2002 Elsevier Science (USA)
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More than 36 million people are today estimated to
have a chronic human immunodeficiency virus type 1
(HIV-1) infection, and the epidemic is responsible for
over 21 million deaths (UNAIDS/WHO, 2000). Highly ac-
tive antiretroviral therapy (HAART) is capable of slowing
down the disease progression to acquired immune de-
ficiency syndrome (AIDS), but fails to clear the HIV-1
infection (Chun et al., 1999; Chun and Fauci, 1999). In
addition, HAART is too expensive to be available world-
wide. The HIV-1 subtype B has gained the most focus
when developing HIV-1 therapies. This is also the most
spread subtype in Western Europe and North America.
Subtypes A and D are predominant in central Africa,
while the southern parts of Africa and India are mainly
afflicted with subtype C (Kuiken et al., 2000). A rising
number of recombinant strains have been reported lately,
where different parts of the genome originate from dif-
ferent viral subtypes. For instance, the most common
strain in Thailand was thought to be subtype E, but is
now considered to be an A/E recombinant with multiple
points of crossover along the subtype A and E genomes,
described as the CRF01_AE subtype (Kuiken et al., 2000).
It is believed that cellular immunity is very important in
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cytotoxic T lymphocytes (CTLs) play a major role in
suppressing the infection (Schmitz et al., 1999; Ogg et al.,
1998). Protection at mucosal surfaces, such as IgA and
CTLs located at the site of infection, are probably also
important, as the virus enters the body via these sur-
faces. In addition, neutralizing antibodies may decrease
viral load in vivo (Shibata et al., 1999; Wahren, 1994). In
summary, a broad immunity is presumably required to
prevent primary HIV-1 infection. Because of its ability to
induce both humoral (Robinson et al., 1993) and cellular
(Ulmer et al., 1993) immune responses, we believe that a
DNA-based vaccine strategy may be advantageous over
other strategies. Plasmid cocktails encoding both regu-
latory and structural genes have been used experimen-
tally to induce immune responses to HIV-1 (Schmitz et al.,
1999; Amara et al., 2001; Barouch et al., 2001; Putkonen
et al., 1998).
A small animal model for experimental HIV-1 infection
is extremely useful in HIV vaccine research. It has pre-
viously been established that primary murine spleno-
cytes can be productively infected by a HIV-1 LAI/murine
leukemia virus (MuLV) pseudovirus (Spector et al., 1990;
Anda¨ng et al., 1999; Lusso et al., 1990). Syngenic mice
can subsequently be challenged with transplanted in-
fected splenocytes and HIV-1-producing cells can be
recovered from the ascites fluid 10 days after challenge
(Isaguliants et al., 2000; Hinkula et al., Unpublished data).
These findings contrast to the inability of murine cell
lines to produce mature HIV (Trono and Baltimore, 1990).
In this study we hypothesize that a multivalent vaccine0042-6822/02 $35.00
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consisting of envelope proteins from subtypes A, B, and
C may elicit antibodies and CTLs with a broad cross-
reactive capacity and may have the ability to neutralize
various viral isolates. We describe the production of such
multivalent vaccines consisting of a mixture of recombi-
nant DNA plasmids encoding subtype-specific gp160s
from HIV-1 subtypes A, B, and C and the regulatory Rev
protein. In addition, we investigate the ability of the
multivalent vaccine to induce immunity to challenge with
a HIV-1/MuLV pseudotype virus in mice.
RESULTS
Cloning
A basic construct encoding the envelope gene from a
subtype B LAI strain was created (pKCMVgp160 B, Fig.
1). The codons of the furin cleavage site responsible for
posttranslational processing of the gp160 precursor pro-
tein in the basic vaccine construct were modified by
site-directed mutagenesis to produce an unprocessed
gp160 precursor protein. The mutations introduced were
the R511S and the A512M (Fig. 2). The gp160 furin cleav-
age sequence, REKRAV (Moulard et al., 1998), was thus
replaced by REKSMV, destroying the cleavage site.
Mosaic gp160 genes were produced by homologous
recombination (Fig. 1). Approximately 75% of the original
subtype B gp120 gene was substituted for that of subtype
A or C. Subtype-specific regions were identified by se-
quencing. Analysis of the mosaic gp160 genes gave the
approximate sites of recombination.
There was some 70% sequence identity between the
subtype B and subtype A and C V3 loops (Fig. 2). The V3
loops also differ in charge between the subtype B V3
loop that have a net charge of 4 and the A and C
sequences which have a net charge of 1 each. This
reflects the coreceptor usage of the original HIV-1 iso-
lates used for the cloning of the vaccine constructs, X4
for the subtype B derived, and R5 for the A and C derived
gp160s, respectively (Speck et al., 1997).
Expression of gp160
Recombinant gp160 was produced in eukaryotic cells
in vitro. This was detected after transfection of HeLa
cells by immunofluorescence (Figs. 3A–3C) and by im-
munoblot (Fig. 3D). In the IF assay, all three constructs
showed equivalent staining patterns, suggesting compa-
rable intracellular processing. The spotty intracellular
appearance could be explained by the presence of gly-
colipid-enriched membrane lipid rafts. Such rafts have
recently been shown to be involved in HIV protein
transportation and viral budding (Nguyen and Hildreth,
2000). The immunoblot was preceded by lectin precipi-
tation. Galanthus nivalis agglutinin (GNA) binds to high
mannose residues that are very rare on intracellular
proteins but present on the heavily glycosylated HIV-1
gp160 protein (Gilljam, 1993). Most of the produced pro-
tein was present as unprocessed gp160, even though
some gp120 was observed in the subtype C construct
(Fig. 3d). No difference in gp160 expression could be
observed either in immunofluorescence or in immuno-
blot.
FIG. 1. Cloning Strategy. Mosaic gp160 constructs for DNA vaccina-
tion were generated by homologous recombination. Approximately 75%
of the original subtype B gp120 gene was substituted for that of subtype
A or C. The recombination is catalyzed by the host’s recombination
system. The three vaccine constructs with the approximate site
of recombination are schematically represented at the bottom. 
indicate the mutations R511S and A512M destroying the furin cleavage
site.
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FIG. 2. Amino acid alignment of gp160. The amino acid sequences of the gp120 part of the gp160 gene encoded by the three vaccine constructs.
The hypervariable loops V1–V5 are highlighted by boxes and have been substituted by the homologous recombination process in the chimeric
constructs A/B and C/B. V3 specific peptides were generated to represent the entire V3 loop from all three constructs.
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Serology and B cell stimulation
Two of the ABC-immunized mice (ABC2:1 and ABC2:2)
responded with high prechallenge anti-gp160 IgG-titers
(Fig. 4A). These animals also responded strongly to the
neutralizing ELDKWA epitope in the gp41 (data not
shown). IgG1/IgG2a ratios (3.8 and 1.6, respectively) in
these mice indicated a Th2-type response in ABC2:1 and
a more balanced response in ABC2:2. After challenge
with HIV-1/MuLV pseudovirus subtype B, high levels of
antibodies were detected in all (6/6) of the animals in
group ABC. At this point an increased production of IgG1
gave a group median IgG1/IgG2a ratio of 5.8. The ABC2:2
mouse had, however, a ratio of 1.1, indicating a more
Th1-like profile. Two individuals in the group receiving
subtype B envelope DNA, animals B1:2 and B2:3,
responded after challenge with antibodies to recombi-
nant subtype B derived gp160 (rgp160) and to the gp41
ELDKWA epitope. The IgG1/IgG2a ratios in these ani-
mals were 4.9 and 5.5, respectively. We were unable to
detect antibodies to gp160 above background levels ei-
ther pre- or postchallenge in groups AC, E, and N. Ani-
mals with antibodies to gp160 also had antibody titers to
the subtype B pool of V3-specific peptides. However, we
could not detect antibodies directed to the A- and C-
pools of V3 peptides in any animal (data not shown).
Fourteen of sixteen of the gp160 gene immunized mice
showed gp160-specific antibody production after antigen
stimulation in vitro with recombinant subtype B derived
gp160, as detected in the B cell stimulation assay (Fig.
4B). Strong responders were seen in the ABC, AC, and B
groups. Neither control immunized mice nor nonimmu-
nized control mice produced any detectable antibodies
to gp160 after antigen stimulation. Some mice in the ABC
and B groups also responded to stimulation with the
B-pool of V3-loop peptides (data not shown). There were
no responders to stimulation with V3 peptides derived
from subtypes A and C.
HIV-1 neutralization
Pooled postchallenge serum from HIV-1 gp160 sub-
type B immunized mice that had gp160-specific IgGs
were capable of efficiently (90%) neutralizing HIV-1 IIIB
and SF2 (Table 2). Both pre- and postchallenge sera from
HIV-1 gp160 subtype ABC DNA immunized animals were
shown to efficiently neutralize HIV-1 IIIB and SF2. Neu-
tralization of HIV-1 subtype B primary isolate 6920 was
less efficient with no neutralization detected in serum
from group B mice, while the group ABC envelope im-
munized mouse serum before challenge showed neu-
tralization at the 50% level. None of the sera were capa-
ble of neutralizing the primary isolate with 66% at
serum dilution 20.
Lymphocyte proliferation
In the lymphocyte proliferation assay all animals in the
ABC group responded broadly after challenge to two or
more of the stimulation antigens (Table 3). In ABC1:1,
some unspecific stimulation was seen. This was proba-
bly due to the ongoing challenge virus infection. In the
AC group there was one animal with a broad response,
whereas there were two strong responders in the B
group. There was no prominent type-specific reactivity to
the A, B, or C peptide pools. Responses in the groups
receiving empty vector DNA and no DNA were undetect-
able or weak in all but one animal having a strong
challenge virus-induced stimulation. As a control antigen
we used a Baculovirus-derived protein.
IFN- and IL-4 production
IFN- increase and IL-4 production were detected by
capture ELISA in 50 l lymphocyte proliferation assay
supernatants (Fig. 5). Regarding the IFN- increase,
there was a statistically significant difference between
the groups for stimulation with rgp160 (P  0.029) and
the B-pool of V3 peptides (P  0.024). Post hoc con-
FIG. 3. In vitro expression. Expression of the gp160 genes was
detected by immunofluorescence (Figures 3A–3C) and immunoblot
(Fig. 3D). In the immunofluorescence assay, the HIV-1 gp160 genes
were expressed transiently in HeLa cells. The images show cells that
are transfected with pKCMVgp160 A/B (3A), B (3B), and C/B (3C),
respectively. All transfections were performed together with the rev
gene. The distinct expression pattern may reflect the location of gp160
to lipid rafts in the cellular membranes. The transfection frequency and
staining patterns seen were comparable for all three constructs. In the
immunoblot (3D) HeLa cells were transiently cotransfected with the
three gp160 constructs, respectively, together with pKCMVrev. Lanes
1–3 depict expression of gp160 A/B, B, and C/B. Lane 4 is the untrans-
fected control. Detection of gp160 was performed with a cocktail
consisting of four monoclonal antibodies. All three constructs ex-
pressed gp160 as estimated by molecular weight and specific antibody
binding. Traces of gp120 were seen in transfections with the subtype C
construct even though most of the protein produced was gp160.
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trasts showed that the ABC group had higher IFN-
increase than the controls after rgp160 stimulation (P 
0.007) and B-pool stimulation (P  0.005). It is inter-
esting to note that all but one of the responding animals
in the T cell proliferation assay also responded with net
increases in IFN- production with 400 pg or more. The
B2:1 mouse had a less pronounced response with a net
IFN- increase of 200 pg. All responders in the IFN-
assay did not, however, respond in the T cell proliferation
assay (data not shown).
For the IL-4 production, there was a statistically sig-
nificant difference between all groups for rgp160 (P 
0.003), A-pool (P  0.019), and B-pool (P  0.010).
Post hoc contrasts showed that the ABC group had
FIG. 4. Antibody production. Antibodies to rgp160 were measured by ELISA in quadruple wells at serum dilution 1/1000 (A). Antibody production
prechallenge (white bars) was detected in two of the ABC immunized mice. Postchallenge antibody production (black bars) was detected in all
ABC-immunized mice and in two of the B-immunized mice. Error bars indicate one standard deviation. In the B cell stimulation assay (B), B cells from
immunized animals were cultured with rgp160. Production of specific antibodies to rgp160 was detected by ELISA in the cell supernatants after 3 days
of stimulation. Fourteen of sixteen immunized animals responded with antibody production, whereas the controls only had background levels. Error
bars indicate 1 standard deviation.
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significantly higher IL-4 production after stimulation with
rgp160 than the AC group (P  0.006) and the controls
(P  0.004). Furthermore, the ABC group had signifi-
cantly higher IL-4 production after stimulation with the
B-pool than the AC group (P  0.005) and the controls
(P  0.003). The gp160 subtype B immunized mice also
differed statistically from the AC immunized group (P 
0.016) after stimulation with rgp160. No statistical sig-
FIG. 5. Cytokine production. Production of the cytokines IFN- and IL-4 was measured in supernatants from the lymphocyte proliferation assay in
a quantitative ELISA and compared to controls. The criterion for post hoc statistical significance was P  0.017. The net IFN- (5A) differed
significantly between the ABC group and the empty vector and naive control groups after stimulation with rgp160 (P  0.007) and with the B-pool
of V3 peptides (P  0.005). Total IL-4 production (B) differed significantly between the ABC group after stimulation with rgp160 and the AC-group
(P  0.006) and the controls (P  0.004). Furthermore, the ABC group had significantly higher IL-4 production after stimulation with the B-pool V3
peptides than the AC group (P  0.005) and the controls (P  0.003). The gp160 subtype B immunized mice also differed statistically from the AC
immunized group (P  0.016) after stimulation with rgp160.
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nificant post hoc contrasts were found for the A pool.
Interestingly, the individuals classified as responders in
the lymphocyte proliferation after stimulation with rgp160
had higher IL-4 production as compared to those clas-
sified as nonresponders (IL-4 median 28.3 pg, range
2.84–71.5 vs median 3.0 pg, range 0–197, respectively;
P  0.012).
Protection against HIV-1/MuLV challenge
Ten days after intraperitoneal challenge with HIV-1/
MuLV-infected cells, cells from the ascites fluid were
collected and cocultured together with human PBMCs
over 24 days. Low HIV-1 p24 production in cocultures
reflect a high level of specific killing of virus-infected
cells and thus a high level of protection. Mice with
OD490 below cutoff (0.11) in the p24 ELISA were consid-
ered protected. At the end of the cocultivation assay, two
of six mice were protected in the ABC group (Fig. 6A).
There were equally two protected animals in the B group.
None of the animals in the AC group, the empty vector
immunized group, or the naı¨ve control group were pro-
tected. Thus, mice immunized with the subtype B env
gene seemed to have a higher degree of protection than
mock-immunized mice or mice immunized with subtypes
A and C gp160 DNA.
The kinetics for p24 production seemed to differ be-
tween the groups. For instance, all control mice were
positive in the p24 detection assay after 8 days of cocul-
ture. At the same time, none of the ABC-immunized mice
produced detectable levels of p24. Therefore, we ana-
lyzed the time required for p24 to rise above the cutoff
(OD490  0.11), which is represented as percentage (%)
protection plotted over time in Fig. 6B. There was a
statistically significant difference between the groups
(P  0.005) and post hoc contrasts below P  0.01
[Bonferroni adjustment according to Holmes (Pett, 1997)]
showed that the rise in p24 above the cutoff was signif-
icantly delayed in the ABC group as compared to the
AC-immunized group (P  0.009), the empty vector
control group (P  0.005), and the naı¨ve controls (P 
0.005). The subtype B immunized group did not, how-
ever, differ significantly from naı¨ve controls (P  0.043)
in this respect.
DISCUSSION
In this study we describe results pointing at enhanced
immune responses after immunization with the gp160
gene derived from HIV-1 subtypes A, B, and C as com-
pared to immunization with subtype B only or with sub-
types A and C in combination. This enhancement con-
tributes to a higher degree of protection to experimental
challenge with a subtype B HIV-1/MuLV pseudotype vi-
rus in the groups where the subtype B construct was
included. The enhancement was observed even though
the amount of subtype B envelope gene was threefold
less in the ABC group than in the B group.
To construct a vaccine with the capability of protecting
against both syncytium-inducing (SI) and non-syncytium-
inducing (NSI) HIV-1 isolates, we have deliberately cho-
sen envelope genes of both kinds, the subtype B LAI
strain being SI and subtype A and C isolates being NSI
(Gilljam, 1993). Homologous recombination was used to
clone in the hypervariable loops of HIV-1 (V1–V5) from
subtypes A and C into a subtype B backbone. The furin
proteolytic cleavage site in the subtype B backbone was
destroyed by site-directed mutagenesis, thus preventing
the maturation of gp160 to gp120 and gp41. The gp160
molecule has higher antigenicity for patient sera than the
gp120 and gp41 molecules separately or combined (B.
Wahren, personal communication). The homologous re-
combination procedure allowed us to keep the altered
furin site in the basic construct, only exchanging the
subtype B variable loops for those of subtypes A and C.
The three constructs encoding the HIV-1 subtype B
envelope gene and the A/B and C/B gp160 chimeras
were used for immunization of C57BL/6 mice. For the
immunizations we used the subtype B envelope gene
alone, subtypes A and C genes in combination, and a
cocktail of subtypes A, B, and C genes (Table 1). All
immunizations were carried out together with the rev
gene, since the Rev protein binds to the rev responsive
element (RRE) in the env mRNA and mediates nuclear
export (Richard et al., 1994).
All mice received the same total amount of DNA. This
means that the ABC-immunized group only received one-
third of the subtype B envelope gene compared to the
B-immunized animals. Therefore it is interesting to note
that the ABC-immunized mice rank as the number one
group in all the immunological assays performed (Table
3 and Figs. 4 and 5). The dose effect seen is also
interesting from a general DNA-vaccine point of view
since most genetic immunization studies point toward
increased responses with increased amounts of DNA in
this window of dosage (Deck et al., 1997). Immune re-
sponses in the B-immunized animals were present but
less distinct than in the ABC group. The overall re-
sponses seen in the animals that received A and C
constructs showed a less potent response. Still the A-
and C-immunized mice elicited B cell (Fig. 4B) and T cell
proliferative responses (Table 3) in three of five animals.
Possibly, the immune response in the subtype A and C
immunized mice was not directed to the V3 loops and
could therefore not be measured in this experimental
setup since recombinant gp160 derived from subtypes A
or C was not available. The variation in immune re-
sponses within the immunized groups, especially in the
ability to produce antibodies to gp160, may be due to a
suboptimal immunization strategy for these particular
antigens. A prime-boost regimen might turn out to be
advantageous, and such experiments are ongoing.
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FIG. 6. Protection against HIV-1/MuLV infection. Mice were challenged with subtype B HIV-1/MuLV pseudotype virus infected syngeneic
splenocytes. Ten days after challenge, cells from the ascites fluid were collected and cocultured with human PBMCs. The ability of immunized mice
to eradicate infected cells was assessed as p24 production in cocultures over time (A). Four mice did not reach the cutoff (ABC1:3, ABC2:2, B1:2, and
B2:3) and were considered protected. The time to reach the cutoff (B) reflects the number of infected cells present in the mouse, and thereby, the
potency of the elicited immune response. There was a considerable delay in onset of p24 production in the ABC-immunized animals as compared
to controls (P  0.005). The criterion for post hoc statistical significance was P  0.017.
51HIV-1 MULTI-env DNA VACCINATION
Immunization with rev has showed great potential in
other studies (Osterhaus et al., 1999; Calarota et al.,
1999). In this experiment, the contribution of Rev was not
evaluated since this variable did not differ between the
immunized groups and since it did not seem to contrib-
ute to protection in the subtypes A and C immunized
mice.
Clearly, the vaccine primed the production of postchal-
lenge antienvelope IgG. In the ABC group, all animals
produced anti-gp160 antibodies after 10 days of in vivo
challenge. Only two of five mice in the B group and none
of the other animals did show antibody production. The
lack of serum antibodies in the AC-immunized mice
might be explained by the finding by Stanfield and col-
leagues that the V3 loop charge may affect the possibility
of the host to generate anti-V3 antibodies (Stanfield et al.,
1999). Therefore, it is possible that the subtype B con-
struct is more efficient in antibody induction. It is also
possible that the linear epitopes represented by the
subtype A and C V3 specific peptides were not recog-
nized, since antibodies after genetic immunization are
mainly directed to conformational epitopes (Attanasio et
al., 1997). Thus, priming with subtypes A and C in com-
bination could indeed still be effective but is not as-
sessed here since the challenge is a subtype B
pseudotype virus. By immunizing mice with the HIV-1
envelope genes representing three subtypes as a mix-
ture as compared with only a single envelope subtype
(B), a more efficient level of HIV-1 neutralizing antibodies
was developed. This was seen most clearly when ana-
lyzing the capacity to neutralize a primary HIV-1 isolate,
which could only be neutralized by the serum from the
ABC mice (Table 2).
Fully protected mice producing undetectable levels of
p24 were found in subtype B and subtypes A-, B-, and
C-immunized groups (Fig. 6A). For the ABC-immunized
group there was a significant delay in the onset of p24
production (Fig. 6B). This is arguably due to fewer in-
fected cells present in the ascites fluid, which in turn
would reflect a more potent immune response against
the HIV-1 challenge. These animals thus seemed to be
able to control the challenge virus better than nonimmu-
nized animals and may resemble the short-term viral
control in certain clinical HIV-1 infections.
It is not known if the HIV-1 produced in the cocultures
always originates directly from the transplanted cells, or
if there is a low level of productive virus replication and
spread in the mouse. The HIV-1 envelope can bind to the
lectin DC-SIGN on dendritic cells (DCs), and the antigen
can be trapped in an infectious form over extended
periods in vivo (Geijtenbeek et al., 2000). HIV-1 virus can
also be harbored by follicular dendritic cells (FDCs) and
kept in its native form for long periods of time. Infectious
replication-deficient HIV-1 has been recovered from
FDCs 30 days after injection of the virus into mice (Smith
et al., 2001). Spetz and colleagues have suggested an-
other possible mode of HIV-1 transmission, namely that
the virus could be transferred via apoptosis to cells
lacking the CD4 receptor (Spetz et al., 1999). All of the
above alternative modes of HIV-1 transmission or stor-
age may contribute to infection of hPBMCs in the cocul-
ture assay.
We could not observe any particular correlates of pro-
tection. This can be illustrated by mice ABC2:1 and
ABC2:2 that both had relatively high prechallenge neu-
tralizing antibody titers (Table 2), good T cell proliferation
(Table 3), and IFN- production and weak but detectable
TABLE 2
HIV-1 Neutralization
Serum titer to HIV-1
IIIB SF2 6920
90% 50% 90% 50% 90% 50%
ABC prechallenge sera 30 30 30 70 20 180
ABC postchallenge sera 120 960 50 850 20 40
B postchallenge sera 100 850 20 70 20 20
Note. Pre- and postchallenge sera from the ABC2:1 and ABC2:2
animals were pooled and postchallenge sera from animals B1:2 and
B2:3 were pooled and assayed for neutralizing antibodies. The HIV-1
neutralizing titers against two laboratory subtype B strains (IIIB and
SF2) and one subtype B primary isolate (6920) are shown. The figures
represent the 90% (IC90) and 50% (IC50) neutralization titers, respec-
tively.
TABLE 1
Immunization Strategy
Group
Animals
(no.) Plasmid
Dose I.M.
(g)
Dose G.G.
(g)
ABC 6 pKCMVgp160 B/A 25 2 0.5 2
pKCMVgp160 B 25 2 0.5 2
pKCMVgp160 B/C 25 2 0.5 2
pKCMVrev 25 2 0.5 2
AC 5 pKCMVgp160 B/A 37 2 0.5 2
pKCMVgp160 B/C 37 2 0.5 2
pKCMVrev 25 2 0.5 2
B 5 pKCMVgp160 B 75 2 1.5 2
pKCMVrev 25 2 0.5 2
E 5 pKCMV 100 2 1.5 2
N 5 Untreated — —
Note. Mice were divided into five groups and plasmid DNA was
administered in the quadriceps muscle (i.m.) at weeks 0 and 6, and by
gene gun at weeks 14 and 28. The ABC group (n  6) was given the
envelope gene from subtypes A, B, and C together with the rev gene.
The AC group (n  5) and the B group (n  5) received the envelope
gene from subtypes A and C, and subtype B, respectively. The E group
(n  5) was mock immunized with the plasmid backbone and the N
group (n  5) was kept as a naı¨ve control. The second gene gun
immunization was preceded by intradermal delivery of 1 g murine
GM-CSF.
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IL-4 secretion (data not shown). Still only ABC2:2 was
protected. However, postchallenge antibody production
was present in all protected animals (ABC1:3, ABC2:2,
B1:2, and B2:3), even though not all animals in the ABC
group capable of anti-gp160 antibody production were
protected. In addition, all of the totally protected mice
produced large amounts of IFN- (a net increase of
500 pg); three of four had pronounced T cell responses
and they were all low in IL-4 production (25 pg). This
was, however, also true for some of the unprotected
mice. These data suggest that a Th1-type profile might
be beneficial for clearing the experimental challenge.
When we consider the antibody subclasses, we note,
however, that only one of the animals has a Th1-type
profile, whereas the others have clear Th2 profiles. Thus,
both antibody production and cellular immune re-
sponses seem to have the ability to contribute to protec-
tion. We therefore suggest that both Th1 and Th2 re-
sponses are of importance. Innate immunity may also be
involved and has repeatedly been shown to be induced
by immunostimulatory sequences (ISS) present in bac-
terial plasmid DNA (Davis et al., 1998; Krieg et al., 1995).
These ISS motifs may indeed explain why the empty
vector DNA-immunized group of mice seemed to have a
somewhat higher degree of protection than the naı¨ve
control group. It appears as if the broader immune re-
sponses elicited, the greater is the probability of being
protected. The most prominent correlate to complete
protection is immunization with the HIV-1 subtype B en-
velope gene.
It is interesting to note that the nonprotected ABC
animals had a considerable delay in p24 production,
indicating a better overall immune control of infected
cells in vivo. In conclusion, there seems to be an en-
hanced immune response after immunization with mul-
tiple HIV-1 genes deriving from subtypes A, B, and C.
Despite a threefold lower dose of the subtype B envelope
gene, the ABC-immunized animals keep the specificity
for the challenge virus and elicit more potent and stron-
ger immune responses. We presently do not know
whether this effect is due to (i) an unspecific adjuvant
effect of the gp160 subtype A and C genes or (ii) induc-
tion of a broader cross-reactive immunity. Improvement
of the quality and magnitude of the immune response
has previously been described by Berman and col-
leagues after immunization with the bivalent gp120 sub-
type B/E vaccine (Berman et al., 1999). It is tempting to
speculate that a broader cross-reactivity is indeed in-
duced after multi-subtype immunization and that the
breadth of the immune response is maintained after
experimental challenge in the ABC-immunized mice.
This hypothesis remains, however, to be tested in an
experimental setting where we can use a subtype A or C
HIV-1 challenge virus. Such experiments are being
planned.
We suggest that the envelope multi-subtype approach
to HIV-1 vaccination should be taken into consideration
when designing clinical protocols for HIV-1 vaccine tri-
als.
MATERIALS AND METHODS
Cloning
The basic vaccine construct was produced by cloning
the HIV-1 subtype B gp160 gene from the pCMV160 (Ishii
et al., 1997) into the DNA-vaccination vector pKCMV (Fig.
1) by standard cloning procedures (Sambrook et al.,
1989). The pKCMV plasmid holds a CMV promotor,
HPV16 poly(A) signal, Escherichia coli origin of replica-
tion and encodes kanamycin resistance. Briefly, the LAI
(a subtype B strain) gp160 gene in the pCMV160 plasmid
was used for PCR amplification of the gp120 part with the
primers ATCAGATAGTCGACCACCATGAGAGTGAAGGAG-
AAAT, CAGATACCATGGATTTTTCTCTCTGCACTCTT, and
the gp41 part with the primers ATCAGATAGTCGACCCAC-
CATGGTGGGAATAGGAGCTTT and AGATAGAATTCTTAT-
AGCAAAATCCTTTCC. PCR fragments were subcloned into
pGEM-T Easy (Promega) and subsequently digested with
SalI/NcoI (Roche) and NcoI/EcoRI (Roche), respectively.
The pKCMV expression vector was linearized with SalI/
TABLE 3
Lymphocyte Proliferation
Antigen
ABC
1:1
ABC
1:2
ABC
1:3
ABC
2:1
ABC
2:2
ABC
2:3
AC
1:1
AC
1:3
AC
2:1
AC
2:2
AC
2:3
B
1:2
B
1:3
B
2:1
B
2:2
B
2:3 E 1 E 2 E 3 E 4 E 5 N 1 N 2 N 3 N 4 N 5
A pool 22 9 9 17 9 — — — — 8 6 19 — 10 — — — — — — — — — — 14 —
B pool 23 — 12 19 — 24 — — — 11 — 18 — — — — — — — — — — — — 8 —
C pool 22 10 12 19 8 8 — — — 9 — 21 — 7 — — — — — — — — — — 12 —
rgp160 41 — — 22 15 — — — — — — 23 — 15 — — — — — — — — — — 16 —
Control 25 — — — — — — — — — — — — — — — — — — — — — — — — —
Note. T-cell proliferation results after stimulation with subtype specific V3 loop peptide pools and recombinant gp160 subtype B. Baculovirus protein
was used as a control antigen. Net cpm 103 above cutoff is represented in the table. The cut off was set by calculating the mean net cpm after
stimulation with the peptide pools (5.7  103) and rgp160 (14  103) in the empty vector immunized (E) and naive (N) groups, plus 2 standard
deviations. The N4 mouse was a strong responder in the T cell proliferation and was consequently excluded from the cutoff calculation. If included,
the cut off was 10  103 and 18  103 for peptides and rgp160, respectively.
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EcoRI and all three fragments were ligated together in one
single step. This introduced the mutations R511S and
A512M, destroying the furin cleavage site responsible for
posttranslational processing of the gp160 protein. The re-
sulting basic vaccine construct pKCMVgp160B was verified
by sequencing (ABI 310, Perkin–Elmer).
By cloning through homologous recombination, we
have replaced the variable regions of one gp160 (sub-
type B in the basic construct) with those of subtype A or
C (Fig. 1). Thus three constructs encoding the most
variable parts from subtypes A, B, and C were produced
(Figs. 1 and 2). The basic construct (pKCMVgp160 B) was
digested with DraIII and MunI (Roche), thus removing
approximately 70% of the original gp120 gene. The re-
maining vector handle was purified on a low-melting
agarose gel (GTG-Nusieve). In parallel, 90% of the gp120
gene was isolated by PCR from already cloned subtype
A (GenBank Accession No. 92UG031) and C (GenBank
Accession No. 92BR025) envelope genes with PCR prim-
ers GGGTACCTGTGTGGAAAGA and TCTCACCACCTCT-
CTCTTTT. These PCR fragments encode the most vari-
able parts of the gp160 protein, such as the V3 loop (Fig.
2). After transformation into competent E. coli, overlap-
ping sequences in the PCR fragments recombine with
homologous sequences of the vector handle (Fig. 1)
(Bubeck et al., 1993; Ljungberg et al., 2000). Mosaic
clones were confirmed by sequencing (ABI 310 and 710,
Perkin–Elmer) using subtype-specific sequencing prim-
ers. The three vaccine constructs are subsequently
referred to as pKCMVgp160 B, pKCMVgp160 A/B, and
pKCMVgp160 C/B.
Expression of gp160
Expression of the recombinant plasmids in eukaryotic
cells was assessed by immunoblotting and immunoflu-
orescence. HeLa cells were grown to 80% confluence for
24 h in 100-mm petri dishes prior to transfection. A
transfection mix was prepared as follows: 40 g of
pKCMVgp160 was mixed with 19.2 l polyethylene imine
(PEI) solution (22.5 mg PEI in 10 ml, H2O at pH 7.0)
together with 20 l 20% glucose solution and diluted to
200 l in H2O. The transfection mixture was diluted in 20
ml IMDM (Life Technologies) and added to the cell cul-
tures. Cells were incubated at 37°C in 5% CO2 for 48 h.
This procedure generally gives a transfection efficiency
of 50% in control transfections.
Immunoblot analysis (Towbin et al., 1979) was per-
formed with G. nivalis agglutinin precipitation. GNA is a
lectin with specificity for high mannose residues present
on gp160 but on few or no cellular proteins (Gilljam,
1993). Briefly, after harvesting of gp160-transfected cells,
gp160 was precipitated with GNA coated to agarose
beads (Sigma–Aldrich, Stockholm, Sweden). Precipita-
tion was performed at 4°C, end-over-end for 2 h. The
beads were collected by centrifugation and washed be-
fore protein denaturation was performed with SDS–sam-
pling buffer (Bio-Rad, Richmond, CA) at 100°C for 5 min.
Samples were loaded onto a 4–15% gradient SDS–PAGE
gel (Bio-Rad). After electroblotting to a nitrocellulose
membrane, protein expression was detected with a
cocktail of murine anti-gp160 antibodies: P4/D10 and
F58/H3 (V3 specific) (Åkerblom et al., 1990), T9 (specific
for the N-terminal of gp120) (Moore et al., 1994), and C8
(gp41 specific) (Abacioglu et al., 1994). Specific antibody
binding was detected with horseradish peroxidase (HRP)
conjugated goat anti-mouse antibodies (DAKO A/S, Den-
mark) with the ECL system (Amersham Pharmacia Bio-
tech).
For immunofluorescence HeLa cells were transfected
as above. After 48 h the cells were washed three times
with PBS and fixed with acetone–methanol (80:20) at
20°C. Cells were washed with PBS and subsequently
blocked with normal goat serum (NGS) and BSA. Expres-
sion of gp160 was detected with murine anti-gp120-V3
antibodies (P4/D10, F58/H3) in 1/400 dilution. Secondary
antibodies (FITC-conjugated goat anti-mouse IgG, DAKO
A/S) were diluted 1/200 in 10% NGS, 0.5 g/ml Hoechst
33258, and 0.1% Tween 20 in PBS. FITC staining was
detected under UV illumination with an Eclipse 600 flu-
orescence microscope (Nikon) connected to an Orca II
digital camera (Hamatsu, Japan).
Immunization
In a previous study, mice were vaccinated intraorally
by jet gun immunization (Lundholm et al., 1999). Single
plasmid immunizations were performed with pKCM-
Vgp160 A/B, B, and C/B, respectively. An additional group
was given a mix of pKCMVgp160 A/B and C/B. Respond-
ers were found in all groups as measured by lymphocyte
proliferation and B cell stimulation (data not shown). We
also observed a trend that mice immunized with the
combination of subtype-specific envelope genes were
better protected to challenge (data not shown). An ex-
tended immunization scheme was therefore used.
Twenty-eight C57BL/6 mice (C57BL6  dba/2 trans-
genic for the human HLA.A2) (Vitiello et al., 1991) were
immunized twice intramuscularly (100 g DNA per im-
munization), followed by two epidermal gene gun immu-
nizations (1.5–2.0 g per delivery). The second gene gun
immunization was preceded (15 min) by intradermal in-
jections of 1 g murine GM-CSF diluted in 50 g ddH2O
(R&D Systems, Oxon, U.K.) (see Table 1 for details). Two
mice, one in the group immunized with subtype A and C
gp160, and one in the group immunized with subtype B,
were killed by its littermates.
Challenge
Production of pseudotype virus has been described
elsewhere (Anda¨ng et al., 1999). Briefly, a CEM B/T cell
line carrying the MuLV genome was superinfected with a
54 LJUNGBERG ET AL.
cell-free HIV-1 LAI virus stock. After 24 h of infection, the
cells were washed extensively to remove excess free
virus and kept until 90–100% cytopathic effect was ob-
tained. Cell-free supernatants were characterized by
testing for production of HIV-1 p24. Mouse splenocytes
were prepared for viral challenge by mashing spleens in
10 ml RPMI 1640 medium followed by centrifugation (360
g for 10 min) and transfer to 96-well plates (400,000 cells
per well). After concanavalin A stimulation for 24 h, the
virus preparation was used to infect the murine spleno-
cytes. Experimental challenge was performed by inject-
ing 106 syngenic murine splenocytes infected with the
HIV-1/MuLV pseudovirus. The infected cells were in-
jected intraperitoneally. After 10 days of in vivo challenge,
cells from the ascites fluid were collected and HIV-1
isolation was performed by coculture with human PBMC
for 24 days. Production of p24 correlates with HIV repli-
cation and production of new HIV virions (Anda¨ng et al.,
1999). Supernatants were collected at days 3, 5, 8, 11, 14,
18, 20, and 24 and assayed for HIV-1 p24 antigen using
an in-house p24 capture ELISA (Devito et al., 2000). HIV-1
was recovered in 40 of 41 of the cocultures with cells
from nonimmunized and empty plasmid mock-immu-
nized animals (J. Hinkula et al., unpublished data).
Production of p24 was monitored over time for each
animal. A standard curve with a linear correlation (R 2 
0.99) between OD490 nm 0.1 and 1.5 (0.033 ng p24/ml to
0.5 ng p24/ml) was produced. However, in samples with
p24 concentrations above 0.5 ng/ml, the linear correla-
tion was lost. This typically occurred in heavily infected
animals from day 8 onward. Therefore, in Fig. 6, p24
production is represented by OD490 nm rather than p24
concentration. A cutoff was set by calculating the geo-
metric mean of the OD490 nm in uninfected control cell
cultures (murine spleen cells, murine spleen cells to-
gether with human PBMCs, human PBMCs, or medium
only), plus 2 standard deviations. The cutoff was set to an
OD490 nm of 0.11. Animals with p24 production below the
cutoff were considered to be protected.
Generating gp120 V3-specific peptides
Subtype-specific peptides corresponding to the entire
V3 loop of the vaccine constructs were synthesized us-
ing F-MOC chemistry with a multiple solid-phase peptide
synthesis method (Leandersson et al., 2000; Levi et al.,
1993). Five 16-mers with eight overlapping amino acids
per subtype were produced according to the V3 se-
quences shown in Fig. 2.
ELISA and B cell stimulation
ELISA was carried out essentially as has been de-
scribed (Lundholm et al., 1999). Briefly, ELISA plates
(Nunc Maxisorp Odense, Denmark) were coated with
V3-specific peptides from subtypes A, B, or C, with a
gp41 ELDKWA epitope peptide, or with recombinant sub-
type B gp160 [MicroGeneSys (now ProteinSciences), Me-
riden, CT]. Serum was diluted and added to wells. Reac-
tive antibodies were detected with goat anti-mouse IgG
antibodies conjugated to HRP (Bio-Rad) diluted 1/5000.
Alternatively, goat anti-mouse IgA HRP antibodies
(Southern Biotechnology, Birmingham, AL) at 1/1000 di-
lution were used. When detecting subtype-specific anti-
bodies, rabbit anti-mouse IgG1 and IgG2a antibodies
(Sigma-Aldrich) were added at 1/1000 dilution. A second-
ary goat anti-rabbit HRP antibody was added at 1/4000
dilution (DAKO PO449). Plates were then developed for
30 min by adding O-phenylene diamine buffer (OPD
buffer). The color reaction was stopped with 2.5 M H2SO4
and the optical density was read at 490 nm.
B cells were stimulated in vitro with different antigens
(peptides and rgp160). Microtiter plates (Nunclon,
Odense, Denmark) were coated with gp120 V3 subtype-
specific peptides (5 g/well) or rgp160 (0.1 g/well).
Plates were washed with 0.9% NaCl. Splenocytes
(100,000) were added to each well and plates were
incubated at 37°C in 6% CO2 for 54 h. The plates were
washed as above and 100 l of goat anti-mouse IgG
antibodies (Bio-Rad) were added at a 1/5000 dilution.
After incubation at 37°C for 1 h, specific antibodies were
detected as was described for ELISA.
HIV-1 neutralization assay
The HIV-1 neutralization assay was performed as pre-
viously described (Hinkula et al., 1994). In brief, mouse
sera were pooled and diluted 1:5 in RPMI 1640 medium
(Gibco, Life Technologies, Scotland) and inactivated at
56°C for 30 min. The inactivated sera were diluted and
used at final dilutions 1/20, 1/80, 1/320, and 1/1280 in
tissue culture plates (Nunc microwell plates, Nunc,
Aahus, Denmark). Diluted sera (75 l/well) were mixed
with three HIV-1 isolates (75 l/well of HIV-1IIIB, HIV-
1SF2, or a primary HIV-1 subtype B isolate 6920). The
serum and virus mix was incubated at 37°C for 1 h
before 100,000 PHA-activated human PBMC in 75 l
were added. The cultures were incubated at 37°C, 5%
CO2 overnight before washing twice with RPMI 1640.
After the final wash each culture well was filled with 250
l RPMI 1640 supplemented with 10% fetal calf serum, 20
IU/ml rIL-2, 4 M 2-mercaptoethanol, 10 M HEPES, and
1% PEST. After 3 days of culture at 37°C, 5% CO2, 150
l/well was exchanged with fresh medium and after 6
days of culture the presence of HIV-1 p24 antigen in the
culture medium was measured.
Lymphocyte proliferation
The lymphocyte proliferation was performed essen-
tially as has been described previously (Ljungberg et al.,
2000). Briefly, microtiter plates (Nunc Maxisorp Odense,
Denmark) were coated with V3-specific peptides from
subtypes A, B, and C or with recombinant gp160 (rgp160).
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Concanavalin A (Con A) was used a as positive control.
Spleenocytes were cocultured with the antigens for 5
days before H3-labeled thymidine was added to each
well and incubated for 16 h. The cells were harvested
and counted in a -counter (Wallac 1450, Turku, Finland).
A net cpm above the cutoff was considered as positive in
the assay and is represented by a plus sign in Table 3.
The cutoff was set by calculating the mean net cpm after
stimulation with the separate peptides, the peptide
pools, and rgp160 in the two groups receiving empty
vector DNA (E group) and no DNA (N group) plus 2
standard deviations. As a control antigen we used a
baculovirus-derived protein.
IFN- and IL-4 production
Interferon- (IFN-) and interleukin-4 (IL-4) production
in lymphocyte proliferation assay supernatants were
measured after 60 h of stimulation, using a capture
ELISA (R&D Systems).
Statistical analysis
Statistical analysis was performed using the SPSS
program version 10.1.0 for Windows. The criterion for
statistical significance was P  0.05. Since most of the
data were not normally distributed, the nonparametric
Kruskal–Wallis test and the Mann–Whitney U test were
used (Pett, 1997). The former test was used initially to
identify differences in the comparisons involving four
groups (the ABC-, AC-, B-groups and the control group
being the empty vector and naı¨ve groups combined), and
the latter for pairwise post hoc comparisons following a
statistically significant Kruskal–Wallis test. To control the
type I error rate for multiple comparisons of five groups,
a P value of 0.017 (Bonferroni adjustment according to
Holmes) was used for the post hoc comparison (Pett,
1997).
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